Juno Therapeutics beats earnings expectations, announces it will drop problem cancer drug by Clare McGrane on March 1, 2017March 1, 2017 at 2:57 pm Seattle-based cancer immunotherapy company Juno Therapeutics handily beat analyst expectations for the fourth quarter, posting $21.2 million in revenue, compared to an expected $14.6 million, with a loss of 51 cents a… Read More